Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

2.4K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.4K
T Cell Types and Functions01:24

T Cell Types and Functions

3.3K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing tyrosine kinase inhibitor sensitivity by restoring IKAROS activity on GLUT1 expression and glycolysis in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Leukemia·2026
Same author

NAMPT inhibition uncovers therapeutic vulnerabilities to venetoclax and chemotherapy in acute myelogenous leukemia.

Leukemia & lymphoma·2025
Same author

SINE compounds activate exportin 1 degradation through an allosteric mechanism.

Nature chemical biology·2025
Same author

PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor-Resistant Chronic Lymphocytic Leukemia.

Blood cancer discovery·2025
Same author

The Novel Immunocompetent Eµ-SOX11CCND1 Mouse Model Phenotypically and Molecularly Resembles Human Mantle Cell Lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment.

The Journal of clinical investigation·2025

Related Experiment Video

Updated: Apr 5, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.8K

Interleukin-6 in CLL: accelerator or brake?

Rosa Lapalombella1

  • 1THE OHIO STATE UNIVERSITY.

Blood
|August 8, 2015
PubMed
Summary

Interleukin-6 (IL-6) produced in the tumor microenvironment suppresses chronic lymphocytic leukemia (CLL) by inhibiting toll-like receptor (TLR) signaling, revealing a novel tumor-suppressive mechanism.

Area of Science:

  • Immunology
  • Cancer Biology
  • Hematology

Background:

  • The tumor microenvironment significantly influences cancer progression and treatment response.
  • Immunoreceptor signaling plays a critical role in immune cell function within the tumor microenvironment.
  • Chronic lymphocytic leukemia (CLL) is a B-cell malignancy with complex interactions involving the tumor microenvironment.

Purpose of the Study:

  • To elucidate the role of interleukin-6 (IL-6) in the context of chronic lymphocytic leukemia (CLL).
  • To investigate the interaction between IL-6 and toll-like receptor (TLR) signaling in the CLL microenvironment.
  • To present a novel mechanism of tumor suppression mediated by microenvironment-derived IL-6.

Main Methods:

  • Analysis of human cancer microenvironment samples.

More Related Videos

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.7K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.3K

Related Experiment Videos

Last Updated: Apr 5, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.8K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.7K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.3K
  • Investigation of immunoreceptor signal interactions.
  • Assessment of IL-6 effects on TLR signaling pathways in CLL cells.

    • Main Results:

    • Microenvironment-produced IL-6 demonstrates a tumor-suppressive function in CLL.
    • IL-6 inhibits toll-like receptor (TLR) signaling pathways.
    • A novel mechanism involving IL-6 and TLRs in CLL tumor suppression was identified.

    Conclusions:

    • IL-6 acts as a tumor suppressor in CLL by modulating TLR signaling.
    • Understanding these interactions provides new insights into CLL pathogenesis.
    • Targeting the IL-6/TLR axis may offer therapeutic strategies for CLL.